Treatment Study
72 patients indicated they took 2CdA treatment as their first series or second series if their first series was Watchful Waiting (14). For this entire group the average response time was 1.89 years and the median response time was 1.74 years. The average age of this group was 59.6 years and the median age was 59.1 years. There dose not seem to be any correlation between age and response time. The age span was from 35 to 78.
29 out of the 72 have indicated they have taken a second series of treatment. The average response time for this group was 1.79 years and the median response time was 1.08 years.
43 patients indicated no other treatment at the time they sent in their profile. The average response time for this group was 2.03 years and the median response time was 1.94 years. If and when profiles are updated with more recent information these numbers need to be recalculated.
13 patients indicated they took a combination treatment with 2CdA. . The average response time for this group was 1.83 years and the median response time was 1.97 years. Only 2 out of the 13 indicated taking a second series of treatment.
Please note the data supplied by patients were ranges not absolute numbers. For this study the average of the range given were used in calculating the following information. These numbers should only be used to show trends.
The average reduction in IgM 6 months after completing the first series of 2CdA was 2000 and the median was 1500 (Out of the 72 patient profiles only 38 had enough data to calculate a 6 month reduction in IgM).
The average reduction in WBC 6 months after completing the first series of 2CdA was 0.9 and median was 0.9
The average increase in RBC 6 months after completing the first series of 2CdA was 0.4 and median was 0.0
The average increase in HGB 6 months after completing the first series of 2CdA was 1.7 and median was 2.5
Definitions of terms:
Average: Add all the values in
a set numbers and then divide that sum by total of numbers in the set.
Median: The value in the
center of a set of values.
Response
time: Is from
the start of a series of treatment to the start of the next series of
treatment.
Series: A set
number of courses of a drug. This is followed by an undetermined
time period not requiring treatment. For example: 3 Courses of 2CdA over a
6 month period (this is one series) or some quantity of Cytoxan daily/weekly
over two years (this is also one series).
|
|
IgM before 1st |
IgM after 1st |
Series1 6 Month reduction |
IgM before 2nd |
IgM Most Recent |
|
Average |
4239.94 |
2358.20 |
2001.33 |
3216.17 |
2261.70 |
|
Median |
3749.50 |
2249.50 |
1500.00 |
2749.50 |
1749.50 |
|
|
WBC before 1st |
WBC after 1st |
Series1 6 Month reduction |
WBC before 2nd |
WBC Most Recent |
|
Average |
4.8 |
4.0 |
0.9 |
10.3 |
4.2 |
|
Median |
4.7 |
3.2 |
0.9 |
4.2 |
4.2 |
|
|
RBC before 1st |
RBC after 1st |
Series1 6 Month reduction |
RBC before 2nd |
RBC Most Recent |
|
Average |
3.4 |
3.9 |
-0.4 |
3.6 |
3.9 |
|
Median |
3.2 |
3.7 |
0.0 |
3.2 |
3.7 |
|
|
HBC before 1st |
HGB after 1st |
Series1 6 Month reduction |
HGB Before 2nd |
HGB Most Recent |
|
Average |
9.8 |
11.6 |
-1.7 |
10.5 |
12.0 |
|
Median |
9.7 |
11.7 |
-2.5 |
10.5 |
12.2 |
Treatment Side Effects
|
Treatment Text |
|
SideEffects Code |
SideEffect Text |
|
|
2Cda (a nucleoside analogue) |
|
1 |
Fatigue |
21% |
|
|
|
2 |
Weakness |
15% |
|
|
|
3 |
Anemia |
11% |
|
|
|
12 |
Weight Loss |
7% |
|
|
|
6 |
Loss of Appetite |
7% |
|
|
|
21 |
Shingles or other Rash |
6% |
|
|
|
4 |
Lethargy |
5% |
|
|
|
19 |
Headaches |
4% |
|
|
|
32 |
Peripheral Neuropathy |
4% |
|
|
|
25 |
Hot, Cold or Swollen Feet |
4% |
|
|
|
9 |
Insomnia |
3% |
|
|
|
7 |
Lack of Concentration |
3% |
|
|
|
99 |
No Side Effects |
17% |
The following data is a small part of the total detail data used to generate all the summary information for this report. The total quantity of material is available upon request.
_______________ indicates patient was on Watchful Waiting before taking their first series of 2CdA.
_______________ indicates patient took a second series of treatment
_______________ indicates patient took a combination treatment with 2CdA.
|
Id |
Private |
Age series1 |
Series |
Treatment |
Date from |
Date to |
Response Time |
Response time |
Response time
(ongoing) |
|
No |
66.56 |
2 |
2Cda (a nucleoside
analogue) |
11/1/1997 |
12/1/1997 |
1.58 |
1.58 |
|
|
No |
52.83 |
1 |
2Cda (a nucleoside analogue) Cytoxan |
3/17/1997 |
7/21/1997 |
|
2.93 |
2.93 |
|
No |
52.27 |
1 |
2Cda (a nucleoside analogue) |
4/1/1996 |
6/1/1996 |
|
3.93 |
3.93 |
|
No |
61.77 |
1 |
2Cda (a nucleoside analogue) Cytoxan Erythropoietin |
11/6/1997 |
11/12/1997 |
|
2.30 |
2.30 |
|
No |
47.77 |
1 |
2Cda (a nucleoside analogue) |
1/1/1999 |
2/1/1999 |
1.08 |
1.08 |
|
_______________ indicates patient was on Watchful Waiting before taking their first series of 2CdA
|
ID |
IgM before 1st |
IgM after 1st |
Series1 .6 Month reduction |
IgM before 2nd |
IgM Most Recent |
WBC before 1st |
WBC after 1st |
Series1 6 Month reduction |
WBC before 2nd |
WBC Most Recent |
RBC before 1st |
RBC after 1st |
Series1 6 Month reduction |
RBC before 2nd |
RBC Most Recent |
HBC before 1st |
HGB after 1st |
Series1 6 Month reduction |
HGB Before 2nd |
HGB Most Recent |
|
2 |
|
|
|
|
|
4.2 |
4.2 |
0 |
|
3.2 |
2.5 |
3.7 |
-1.2 |
|
3.7 |
6.2 |
12.2 |
-6 |
|
11.7 |
|
6 |
5249.5 |
3249.5 |
2000 |
|
1249.5 |
4.7 |
2.2 |
2.5 |
|
2.2 |
3.2 |
3.2 |
0 |
|
3.7 |
11.2 |
11.7 |
-0.5 |
|
14 |
|
22 |
7749.5 |
3749.5 |
4000 |
|
2749.5 |
1.7 |
1.7 |
0 |
|
4.7 |
|
|
|
|
|
7.2 |
|
|
|
11.7 |
|
24 |
2249.5 |
1249.5 |
1000 |
|
2249.5 |
1.7 |
3.2 |
-1.5 |
|
3.2 |
3.7 |
3.7 |
0 |
|
3.7 |
7.2 |
12.7 |
-5.5 |
|
11.7 |
|
30 |
2249.5 |
1249.5 |
1000 |
2749.5 |
1249.5 |
4.7 |
4.7 |
0 |
4.7 |
3.7 |
|
|
|
|
|
9.2 |
11.2 |
-2 |
10.45 |
12.2 |